Craft

Eagle Pharmaceuticals

Stock Price

$0.4

2024-10-29

Market Capitalization

$5.2 M

2024-10-29

Revenue

$316.6 M

FY, 2022

Eagle Pharmaceuticals Summary

Company Summary

Overview
Eagle Pharmaceuticals is a specialty pharmaceutical company, focusing on developing and commercializing injectable products primarily in the critical care and oncology areas. The Company offers argatroban for heparin-induced thrombocytopenia, Ryanodex for malignant hyperthermia, non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head and neck cancers/gastric adenocarcinoma, as well as Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Type
Public
Status
Active
Founded
2007
HQ
Woodcliff Lake, NJ, US | view all locations
Website
http://eagleus.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Scott Tarriff

    Scott Tarriff, Chief Executive Officer, President and Board Member

    • Daniel O'Connor

      Daniel O'Connor, Chief Strategy Officer, Head of Corporate Development

    • Brian Cahill, Chief Financial Officer

    • Michael Graves, Chairman of the Board

      LocationsView all

      2 locations detected

      • Woodcliff Lake, NJ HQ

        United States

        50 Tice Blvd #315

      • Chicago, IL

        United States

        Chicago, IL, USA

      Eagle Pharmaceuticals Financials

      Summary Financials

      Revenue (Q2, 2023)
      $64.6M
      Gross profit (Q2, 2023)
      $47.8M
      Net income (Q2, 2023)
      $5.2M
      Cash (Q2, 2023)
      $15.4M
      EBIT (Q2, 2023)
      $10.3M
      Enterprise value
      $60.0M

      Footer menu